Cancer therapy: Can the challenge be MET?

Simona Corso, Paolo M. Comoglio, Silvia Giordano

Research output: Contribution to journalArticlepeer-review

Abstract

The deregulation of tyrosine kinase receptors (RTKs) is frequent in human tumors and is often associated with the acquisition of an aggressive phenotype. The Met oncogene, encoding the RTK for hepatocyte growth factor (HGF), controls genetic programs leading to cell growth, invasion and protection from apoptosis. The deregulated activation of Met is crucial not only for the acquisition of tumorigenic properties but also to achieve an invasive phenotype. The involvement of MET in human tumors has been definitively established and can be achieved through several mechanisms, including MET interaction with unrelated membrane receptors, such as integrins, plexins, CD44, FAS and other RTKs. Interfering with Met activation is thus a new and challenging approach to hamper tumorigenic and metastatic processes.

Original languageEnglish
Pages (from-to)284-292
Number of pages9
JournalTrends in Molecular Medicine
Volume11
Issue number6
DOIs
Publication statusPublished - Jun 2005

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Cancer therapy: Can the challenge be MET?'. Together they form a unique fingerprint.

Cite this